Jonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E Pink, Diego Ruiz Dasilva, Shawn G Kwatra, Yousef Binamer, Norito Katoh, Valeria Aoki, Alvaro Moreira, Ayman Grada, Chao Li, Brian Calimlim, Wan-Ju Lee, Christopher G Bunick
{"title":"实现最佳治疗目标和最小疾病活动对特应性皮炎患者健康相关生活质量和满意度的影响","authors":"Jonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E Pink, Diego Ruiz Dasilva, Shawn G Kwatra, Yousef Binamer, Norito Katoh, Valeria Aoki, Alvaro Moreira, Ayman Grada, Chao Li, Brian Calimlim, Wan-Ju Lee, Christopher G Bunick","doi":"10.1007/s13555-025-01469-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.</p><p><strong>Methods: </strong>Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15 mg or 30 mg, or placebo for the first 16 weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient's HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.</p><p><strong>Results: </strong>Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1-20.2-fold for optimal versus moderate, 1.3 to > 50-fold for optimal versus neither target, and 1.2-16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.</p><p><strong>Conclusions: </strong>These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2255-2273"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256389/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.\",\"authors\":\"Jonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E Pink, Diego Ruiz Dasilva, Shawn G Kwatra, Yousef Binamer, Norito Katoh, Valeria Aoki, Alvaro Moreira, Ayman Grada, Chao Li, Brian Calimlim, Wan-Ju Lee, Christopher G Bunick\",\"doi\":\"10.1007/s13555-025-01469-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.</p><p><strong>Methods: </strong>Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15 mg or 30 mg, or placebo for the first 16 weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient's HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.</p><p><strong>Results: </strong>Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1-20.2-fold for optimal versus moderate, 1.3 to > 50-fold for optimal versus neither target, and 1.2-16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.</p><p><strong>Conclusions: </strong>These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.</p>\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"2255-2273\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256389/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01469-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01469-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介：瞄准更高的湿疹/特应性皮炎倡议的指南确定了临床报告结果（ClinROs）和患者报告结果（PROs）的适度和最佳治疗目标，并定义了最小疾病活动（MDA）同时满足ClinRO和PRO的最佳目标。本事后分析调查了实现个体最佳目标或MDA对特应性皮炎患者健康相关生活质量（HRQoL）结果的影响。方法：来自3期Measure Up 1 （NCT03569293）、Measure Up 2 （NCT03607422）和AD Up （NCT03568318）的患者以1:1:1的比例随机分配，在前16周接受每日口服15 mg或30 mg的upadacitinib或安慰剂。无论是否进行干预，患者均被纳入该分析，并被分为三个相互排斥的反应组，分别满足每种ClinRO或PRO的最佳、中等或两者均不满足的治疗目标，并在第16周达到MDA。对患者HRQoL的影响是通过8个结果来衡量的：瘙痒、皮肤症状、生活质量、睡眠、日常活动、情绪状态、工作效率和治疗满意度。结果：达到最佳治疗目标的患者，与达到中度或未达到治疗目标的患者相比，报告患者HRQoL结果的改善更大（最佳组为1.1-20.2倍，最佳组为1.3 - 50倍，无目标组为1.3 - 50倍，中度组为1.2-16.3倍，无目标组为1.2-16.3倍）。此外，与单独获得最佳ClinRO或PRO的患者相比，获得MDA的患者更有可能报告患者HRQoL结果的改善。结论：这些结果突出了达到最佳治疗目标和MDA在特应性皮炎疾病管理中的价值。
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.
Introduction: Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.
Methods: Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15 mg or 30 mg, or placebo for the first 16 weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient's HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.
Results: Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1-20.2-fold for optimal versus moderate, 1.3 to > 50-fold for optimal versus neither target, and 1.2-16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.
Conclusions: These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
